CLEE011XUS03; Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors
Study of Investigational Medication for CDK4/6 Pathway Activated Tumors
Brief description of study.
The purpose of this signal seeking study is to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.
Detailed description of study
The purpose of this signal seeking study is to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Tumor
-
Age: 18 years - 100 years
-
Gender: All
This study investigates the effects of an investigational medication on solid tumors and blood cancers that are activated by the CDK4/6 pathway. The CDK4/6 pathway is a series of proteins in the body that help control cell division. When this pathway is overly active, it can lead to cancer growth.
Participants in the study will receive the investigational medication to evaluate its efficacy. The study aims to gather data on how well the medication works in treating these specific types of cancer.
- Who can participate: Eligibility criteria include participants with specific health conditions related to CDK4/6 pathway activation, and may specify an age range.
- Study details: Participants will receive the investigational medication to assess its effects on their cancer. The study will focus on gathering data about the medication's efficacy.
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or